Publications

Correction: Overcoming acquired resistance to cetuximab by dual targeting HER family receptors with antibody-based therapy. Iida M, Brand TM, Starr MM, Huppert EJ, Luthar N, Bahrar H, Coan JP, Pearson HE, Salgia R, Wheeler DL.Mol …

IFNγ and TNFα optimize salivary gland mesenchymal stromal cells: an alternative to marrow- and adipose-MSCs for radiation xerostomia. Larsen MC, Gurevic I, Berube L, Vande Loo A, Hanson E, Adam R, Manfrè V, Parker M, …

High-risk neuroblastoma as a model for immunotherapy of non-immunogenic cancers: where might we be in 20 years? Sondel PM, Rakhmilevich AL, Ansari IH, Erbe AK.J Immunother Cancer. 2025 Oct 31;13(10):e013267. doi: 10.1136/jitc-2025-013267.PMID: 41176314 Free article. Review. Deep learning-based …

Immune and Genomic Heterogeneity of MET-Altered Non-Small Cell Lung Cancer. Liu M, Minne RL, Javeri S, Johnson DB, Tomlins SA, Kimple RJ, Baschnagel AM.JCO Precis Oncol. 2025 Sep;9:e2500048. doi: 10.1200/PO-25-00048. Epub 2025 Sep 26.PMID: 41004700 Accelerating …

Adverse prognosis gene expression patterns in metastatic castration-resistant prostate cancer. Sharifi MN, Feng E, Rydzewski NR, Taylor AK, Sperger JM, Shi Y, Helzer KT, Bootsma ML, Carreno V, Chang AH, Nunamaker LA, Blitzer GC, Shang …